BPC-157

BPC-157 is a synthetic pentadecapeptide studied in rodent injury models for its interactions with angiogenic and cytoskeletal signaling pathways.

Yes. 12 third party certificates for BPC-157 are published on this site, covering endotoxin, purity and sterility. Each one is the report as the testing laboratory issued it, not a retyped summary, and the most recent lot is 10mg · 3/3/2026. Match the batch on your vial to the batch on the report.

137525-51-0. It is printed in the specification table on this page so it can be checked against your own records before ordering.

Refrigerate (2-8 deg C) Lyophilized powder is the stable form; once reconstituted, a solution is far more fragile and should be aliquoted rather than repeatedly frozen and thawed.

>=99% by HPLC. The released figure for any given lot is on that lot's certificate rather than taken from this page, because purity is a property of a batch and not of a product line.

No. This is sold for laboratory research use only. It is not a drug, not a supplement, and not approved by the FDA for human or veterinary use. We do not provide dosing, administration, or protocol guidance, by phone, by email, or through the assistant on this site.

No completed, peer-reviewed, controlled human clinical trial of BPC-157 has been published. The peptide entered early clinical evaluation under the development code PL 14736 for inflammatory bowel disease, but publicly available results from that program are limited and no derived product reached approval. Claims about human outcomes are extrapolations from rodent work.

The original characterization reported that the peptide remained intact in human gastric juice for an extended period under the specific in vitro conditions tested. That finding is about resistance to proteolysis in a defined assay. It is not a statement about bioavailability, absorption, or systemic exposure in any species.

It denotes the position of the fifteen-residue fragment within the parent Body Protection Compound sequence as numbered in the original characterization. The number is a positional label, not a version or a potency designation.

They are studied through different mechanistic entry points. BPC-157 work centers on angiogenic receptor signaling and focal adhesion turnover in a fifteen-residue synthetic fragment. TB-500 work derives from thymosin beta-4, a naturally occurring forty-three-residue actin-sequestering protein, and centers on cytoskeletal dynamics. Both literatures are dominated by animal models.

Yes. The World Anti-Doping Agency added BPC-157 to its Prohibited List in 2022 under the category covering non-approved substances. That classification reflects the absence of regulatory approval for human use in any jurisdiction.

No. HPLC purity describes the fraction of peptide-related material that is the target sequence. Net peptide content also depends on residual water, counterion, and solvent, which are reported separately. A certificate of analysis should be reviewed for each lot rather than inferred from the purity figure alone.